Key Insights

Highlights

Treatment Research

1 treatments under study, led by 225acpsmatrillium Bay3563254

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT06217822Phase 1Recruiting

First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Showing all 1 trials

Research Network

Common Treatments

  • 225acpsmatrillium Bay35632541

Active Sponsors

  • Bayer Consumer Care AG1
  • Bayer1

Related Conditions

  • Prostate Specific Membrane Antigen Psma Expression1
  • Advanced Metastatic Castrationresistant Prostate Cancer1

Activity Timeline